SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-162652
Filing Date
2024-06-17
Accepted
2024-06-17 16:35:31
Documents
13
Period of Report
2024-06-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d831468d8k.htm   iXBRL 8-K 24853
  Complete submission text file 0001193125-24-162652.txt   150197

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20240612.xsd EX-101.SCH 2836
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20240612_lab.xml EX-101.LAB 18758
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20240612_pre.xml EX-101.PRE 11701
16 EXTRACTED XBRL INSTANCE DOCUMENT d831468d8k_htm.xml XML 3780
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 241048798
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)